Gary Nachman News
-
As American billionaire Phillip Frost prepared to take over as chairman of Teva Pharmaceutical Industries Ltd. in March 2010, some investors fretted about what would become of Israel’s crown jewel.
-
Teva Pharmaceutical Industries Ltd.’s fourth-quarter earnings fell 19 percent as generic-drug sales dropped and competition hurt the Provigil sleep-disorder pill.
-
Bets on Teva Pharmaceutical Industries Ltd.’s decline are rising to the highest in a year on concern the Israeli drugmaker won’t succeed in blocking competition for its best-selling Copaxone treatment.
-
Valeant Pharmaceuticals International Inc. is in talks with “multiple” potential acquisition targets after it was thwarted in an effort to take over Cephalon Inc., Chief Executive Officer Michael Pearson said.
-
Teva Pharmaceutical Industries Ltd. tumbled the most last week in New York in 16 months on concern the strategy Chief Executive Officer Jeremy Levin unveiled for the Israeli drugmaker won’t be enough to sustain profit growth.
-
Valeant Pharmaceuticals International Inc., Canada’s biggest drugmaker, said no agreement has been reached on its hostile $327 million offer for Ista Pharmaceuticals Inc.
-
Allergan Inc. and Johnson & Johnson breast implants were linked in a U.S. review to a rare type of cancer, challenging again the safety of the decades-old products.
-
Tyler Hurst swiped his debit card at a Walgreens pharmacy in central Phoenix and kicked off an international odyssey of corporate tax avoidance.
-
Forest Laboratories Inc. needs acquisitions to counter a projected 80 percent drop in profit this year as patents on its top-selling drugs start to expire.
-
Allergan Inc., the maker of Botox, said second-quarter profit rose 2.7 percent and raised its earnings forecast on higher sales of the wrinkle smoother and breast implants.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page